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 2 
ABSTRACT 1 
Background: Inter-laboratory variability in quantifying pathogens involved in viral disease after 2 
transplantation may have a great impact on patient care, especially when pre-empitive strategies are 3 
used for prevention.  4 
Objectives: The aim of this study was to analyze the variability in quantifying CMV, EBV and 5 
BKV DNA among 15 virology laboratories of the Italian Infections in Transplant Working Group 6 
(GLaIT) involved in monitoring transplanted patients. 7 
Study Design: Panels from international Quality Control programs for Molecular Diagnostics 8 
(QCMD, year 2012), specific for the detection of CMV in plasma, CMV in whole blood (WB), 9 
EBV and BKV were used. Intra- and inter-laboratory variability, as well as, deviation from QCMD 10 
consensus values were measured. 11 
Results: 100% specificity was obtained with all panels. A sensitivity of 100% was achieved for 12 
EBV and BKV evaluation. Three CMV samples, with concentrations below 3 log10 copies/ml, were 13 
not detected by a few centers. Mean intra-laboratory variability (% CV) was 1.6 for CMV plasma 14 
and 3.0 for CMV WB. Mean inter-laboratory variability (% CV) was below 15% for all the tested 15 
panels. An higher inter-laboratory variability was observed for CMV WB with respect to CMV 16 
plasma (3.0 vs 1.6% CV). The percentiles 87.7%, 58.6%, 89.6% and 74.7% fell within ± 0.5 log10 17 
difference of the consensus values for CMV plasma, CMV WB, EBV and BKV panels, 18 
respectively. 19 
Conclusions: An acceptable intra- and inter-laboratory variability was observed in this study, in 20 
comparison with international standards. However, further harmonization in viral genome 21 
quantification is reasonable expectation for the future. 22 
Keywords: multicenter evaluation; standardization; transplantation; CMV-DNA; EBV-DNA; 23 
BKV-DNA 24 
 25 
26 
 3 
1. Background 1 
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are major causes of post-transplant viral 2 
disease both in solid organ and hematopoietic stem cell transplantation, while Polioma BK virus 3 
reactivation, with virus-associated nephropathy, represents the most frequent cause of graft loss 4 
after renal transplantation [1,2]. The reliability and accuracy of viral load determination are 5 
therefore critical for the management of transplant patients. In fact, virological monitoring of 6 
transplanted patients is based on standardized protocols for genome quantification in order to apply 7 
clinical cut-offs in pre-emptive approaches for disease prevention [3-6]. However, measurements of 8 
viral load performed with commercially available assays might differ significantly, particularly 9 
according to the extraction method used, which is a source of variability with different clinical 10 
specimens. Finally, there is a need for an inter-laboratory comparison of results and evaluation of 11 
individual assays with standardized panels, particularly with collaborative multicentre networks. 12 
 13 
2. Objectives  14 
The aim of this study was to analyze the variability obtained among 15 Italian virology 15 
laboratories, belonging to the Working Group for Transplantation (Gruppo di Lavoro Infezioni nel 16 
Trapianto, GLaIT) of the Italian Association of Clinical Microbiologists (Associazione 17 
Microbiologi Clinici Italiani, AMCLI). Therefore, panels from international Quality Control 18 
programs for Molecular Diagnostics (QCMD, year 2012), specific for the detection and 19 
quantification of CMV in plasma, CMV in whole blood (WB), EBV and BKV were used.  20 
 21 
3. Study design 22 
3.1. QCMD samples 23 
The QCMD panels used in the study were: QCMD 2012 CMV plasma, QCMD 2012 CMV WB, 24 
QCMD 2012 EBV and QCMD 2012 BKV-JCV. A number of samples with various amounts of the 25 
 4 
different viruses suspended in an appropriate matrix and negative controls were tested in each 1 
panel. For a detailed description and composition of the panels see www.qcmd.org.  2 
 3 
3.2. Extraction and quantitative real-time PCR assays 4 
Each sample was tested by each of the laboratories using commercial and in house methods 5 
adopted for routinely virologic monitoring of transplanted patients (Table 1). Nucleic acid 6 
extraction was performed by the majority of the laboratories using automatic extraction with 7 
commercial with sometimes in-house modifications; Real-time PCR amplification was carried out 8 
by all the laboratories with commercially available kits, with only one exception. Quantitative 9 
results were expressed as log10 copies/ml for all three viruses tested. For positive samples detected 10 
below the lowest limit of quantification, when a detected number of copies was not available, an 11 
arbitrary value of half of the lowest limit of quantification was used. 12 
 13 
3.3. Statistical analysis 14 
Intra- and inter-laboratory variability was calculated, as well as, variation with respect to the 15 
QCMD consensus as the coefficient of variation (%CV). The Pearson correlation analysis and the 16 
Bland-Altman analysis were performed to examine the level of agreement between the 15 17 
laboratories’ results and the QCMD samples. Results were considered to be quantitatively 18 
discordant when the results of the Bland-Altman analysis were discordant by more than ±0.5 Log10 19 
of the QCMD consensus values. Statistical analysis was performed using Graph Pad Prism 20 
software, version 5.00.288. 21 
 22 
4. Results  23 
The results obtained by the different GLaIT laboratories were analyzed to obtain a description of 24 
intra- and inter-laboratory variability and a quantitative comparison with respect to the consensus 25 
values reported by the different QCMD panels.  26 
 5 
For each of the four panels tested (QCMD CMV plasma, CMV WB, EBV and BKV) no false 1 
positive results were obtained by any of the GLaIT laboratories (specificity 100%). A sensitivity of 2 
100% was achieved with the EBV and BKV evaluations. Concerning the CMV plasma panel, 3 
sample #3 (2.24 log10 copies/ml) was not detected by 1/15 (6.6%) centres and sample #4 (2.08 log10 4 
copies/ml) was not detected by 4/15 (26.6%) centres. For the CMV WB panel only sample #8 (2.58 5 
log10 copies/ml) was not detected by 4/13 (30.8%) centres. For the BKV/JCV panel, no cross 6 
reactivity with the JCV virus was observed (6 samples) and all of the centres detected all the five 7 
samples containing BKV. 8 
The QCMD CMV plasma and WB panels contained duplicate samples to allow intra-laboratory 9 
variability evaluation. The results indicated that the mean intra-laboratory % of the coefficient of 10 
variation (CV) was 1.6 for CMV plasma and 3.0 for CMV WB.  11 
In Table 2, for each sample the mean, standard deviation (SD), CV (%), median and range of 12 
log10 copies/ml are reported. The mean SD for CMV plasma, CMV WB, EBV and BKV were 13 
respectively 0.27, 0.49, 0.25 and 0.37. The mean % CV for CMV plasma, CMV WB, EBV and 14 
BKV were respectively: 9.4%, 13.7%, 6.71% and 13.3%. The mean Delta log10 for CMV plasma, 15 
CMV WB, EBV and BKV were respectively: 0.93, 1.40, 0.97 and 1.29. It should be emphasized 16 
that the variability was usually larger when considering samples with a virus concentration lower 17 
than 3 log10 copies/ml. 18 
In order to compare the results obtained by the different GLaIT laboratories with those of the 19 
international quality control study, consensus values for each QCMD panel were extrapolated and 20 
used for comparison. Significant correlations were observed in CMV WB, CMV plasma, EBV and 21 
BKV panel results with the Spearman coefficient which ranged from 0.82 to 0.96 (data not 22 
showed). Bland-Altman plots were used to describe the log10 difference between the GLaIT 23 
laboratory results and the consensus values (Figure 1). According to previous reports [7-9], ±0.5 24 
log10 was considered an acceptable variability. In CMV the plasma panel, 114/130 (87.7%) of the 25 
determinations were within ±0.5 log10 difference, while in the CMV WB panel only 51/87 (58.6%) 26 
 6 
were within ±0.5 log10 difference. In the CMV plasma panel, the majority of the discordant results 1 
(14/16, 87.5%) were observed in samples with a <3.0 log10 DNA copies number (Figure 1A), while 2 
in the CMV WB panel discordant results were observed for all sample concentrations (Figure 1B). 3 
In the EBV panel (Figure 1C), 120/134 (89.6%) of the measurements were within a ±0.5 log10 4 
difference, with no evident differences among different sample concentrations. In the BKV panel 5 
(Figure 1D), a total of 56/75 (74.7%) determinations fell within ±0.5 log10 difference; and for the 6 
EBV panel, no differences among the different sample concentrations were detected.  7 
 8 
5. Discussion 9 
Since significant inter-laboratory variability in quantifying CMV, EBV and BKV genomes may 10 
impact the quality of transplanted patient care, especially when pre-empitive strategies are used for 11 
prevention, initiatives aimed at harmonizing viral genome quantification among different 12 
laboratories should always be encouraged. In fact, transplant centres collect patients from all 13 
Italians regions while post-transplant monitoring may be carried out by local laboratories. To the 14 
best of our knowledge, this is the first report which simultaneously measures variability in 15 
quantifying CMV, EBV and BKV DNA which represent the three major viral pathogens 16 
responsible for disease in solid organ transplantation.  17 
Mission of the GLaIT group is to improve standardization of diagnostic procedures for 18 
microbiological monitoring of solid organs and stem cell transplant recipients. Two different studies 19 
aimed to measure variability in CMV and EBV DNA quantification have already been performed 20 
[9,10]. Concerning CMV, the present study, in contrast with the 2009 report [9], takes into account 21 
both CMV DNA quantification in plasma and WB. As for the former CMV study, no false positive 22 
samples were obtained and a sensitivity of 100% was obtained in samples with a DNA load greater 23 
than 3 log10 copies/ml. Although in the past a variability of less than 1 log10 was obtained only in 24 
samples with a viral load greater than 3.7 log10 copies/ml, the results reported here ranged from 0.93 25 
to 1.40 log10 variation for plasma and WB even when considering samples with concentrations 26 
 7 
below 3.0 log10 copies/ml. A greater variability was observed for CMV in WB with respect to 1 
plasma; this is in line with the more complex matrix represented by blood, where nucleic acid 2 
extraction is more laborious. At the same time, the CMV blood panel results, although more 3 
variable, display a greater linearity. Overall, the % accuracy measured fell within ±0.5 log10 and 4 
ranged from 58.6% to 89.6%. This accuracy measured in a multicentre study is considered 5 
acceptable and is higher than those observed in a similar study including fewer centres (n=4) [11].   6 
It should be underlined that in the present CMV quantification analysis, in contrast with previous 7 
studies, all of the laboratories, with only one exception, used a commercial real-time PCR method 8 
and only three different real-time methods were used. These real-time methods were however 9 
associated with a variety of different manual or automated commercial and in house modified 10 
protocols for nucleic acid extraction. It is reasonable to suppose that much of the variability 11 
observed among the different quantifications was associated with the extraction procedures, rather 12 
than the PCR amplification. This was also the case for EBV and BKV DNA determinations, where 13 
as for CMV DNA, no false positive results were obtained for any samples. In the present study, the 14 
best results (lower variability) were obtained with the EBV DNA panel. However, no direct 15 
comparison can be made with the previous EBV study [10] due to the different composition of the 16 
panels used for the evaluation. For BKV DNA, no cross reactivity was observed for samples 17 
positive for the other Poliomavirus (JCV), included in the same QCMD panel and, although this 18 
represents the first study by our group on quantification of this virus, an acceptable level of 19 
variability was achieved. International standards are available since 2011 for CMV DNA and 2012 20 
for EBV DNA [12, 13]; this represents an opportunity to improve harmonization in CMV and EBV 21 
genome quantification.  22 
In conclusion, the results of this multicentre study indicate that CMV, EBV and BKV DNAemia 23 
are quantified with acceptable variability using a variety of extraction volumes and protocols with 24 
different commercial and in-house molecular protocols.  25 
 26 
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Figure Legend  1 
Figure 1. Bland-Altman plots are used to describe the Log difference between the GLaIT 2 
laboratory results and QCMD consensus values. A (CMV plasma panel), B (CMV WB panel), 3 
C (EBV panel) and D (BKV panel). 4 
 5 
 14 
Table 1. Methods for viral DNA extraction and quantification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Virus 
target 
Center 
# 
Nucleic acid extraction Input volume (µl) Output volume (µl) Amplification method Real-time PCR 
instrument 
Instrument  Protocol     
CMV 1 QIA Symphony DSP virus/pathogen (modified) 400 (200 for WB) 90 (90 for WB) CMV Trender Affigene Stratagene xp3000 
2 NucliSENS EasyMag generic 2.0.1 250 (100 for WB) 25 (25 for WB) CMV Alert Real-Time, ELITechGroup ABI Prism 7300 
3 QIA Symphony DSP virus/pathogen (modified) 1000 110 CMV ELITe MGB Kit, ELITechGroup ABI Prism 7300 
4 NucliSENS EasyMag generic 2.0.1 and specific 2.0 for WB 500 (200 for WB) 55 (55 for WB) in house PCR (target US8)[14] ABI Prism 7300 
5 NucliSENS EasyMag generic 2.0.1 100 50 CMV ELITe MGB Kit, ELITechGroup ABI Prism 7300 
6 x-tractor gene UV light Helix DNA Corbet 400  
200 for WB 
60  
150 for WB 
CMV Alert Real-Time, ELITechGroup 
CMV ELITe MGB Kit, ELITechGroup 
ABI Prism 7300 
7 NucliSENS EasyMag 
QIA Symphony 
generic 2.0.1                                                  
blood 200V6  for WB 
500      
200 for WB  
50                         
200 for WB 
CMV ELITe MGB Kit, ELITechGroup ABI Prism 7500 
8 NucliSENS EasyMag generic 2.0.1 400 (200 for WB) 60 (85 for WB) CMV Alert Real-Time, ELITechGroup ABI Prism 7300 
9 NucliSENS EasyMag generic 2.0.1 1000 (200 for WB) 25 (55 for WB CMV Alert Real-Time, ELITechGroup ABI Prism 7300 
10 QIA Symphony DSP virus/pathogen and DSP DNA for WB 500 (200 for WB) 90 (90 for WB) CMV ELITe MGB Kit, ELITechGroup ABI Prism 7300 
11 QIA Symphony DSP virus/pathogen and DSP DNA for WB 500 (200 for WB) 140 (90 for WB) CMV ELITe MGB Kit, ELITechGroup ABI Prism 7300 
12 NucliSENS EasyMag specific 2.0 (modified for WB) 500 (100 for WB) 100 (50 for WB) CMV ELITe MGB Kit, ELITechGroup ABI Prism 7300 
13 NucliSENS EasyMag generic 2.0.1 500 (100 for WB) 55 (55 for WB) CMV Alert Real-Time, ELITechGroup ABI Prism 7300 
14 NucliSENS EasyMag generic 2.0.1 500 (200 for WB) 55 (55 for WB) CMV Alert Real-Time, ELITechGroup ABI Prism 7300 
15 Manual extraction QIAamp blood mini kit 200 100 CMV r-gene Argene-Biomerieux ABI Prism 7500 
        
EBV 1 QIA Symphony DSP virus/pathogen 400 90 EBV Trender Affigene Stratagene xp3000 
2 NucliSENS EasyMag generic 2.0.1 250 25 EBV Alert Real-Time, ELITechgroup ABI Prism 7300 
3 NucliSENS EasyMag generic 2.0.1 500 55 EBV ELITe MGB Kit, ELITechgroup ABI Prism 7300 
4 NucliSENS EasyMag generic 2.0.1 500 55 in house PCR (target EBNA-1)[15] ABI Prism 7300 
5 NucliSENS EasyMag generic 2.0.1 100 100 EBV ELITe MGB Kit, ELITechgroup ABI Prism 7300 
6 x-tractor gene UV light Helix DNA Corbet 400 60 EBV Alert Real-Time, ELITechgroup ABI Prism 7300 
7 NucliSENS EasyMag generic 2.0.1 500 50 EBV ELITe MGB Kit, ELITechgroup ABI Prism 7500 
8 NucliSENS EasyMag generic 2.0.1 400 60 EBV Alert Real-Time, ELITechgroup ABI Prism 7300 
9 NucliSENS EasyMag generic 2.0.1 1000 25 EBV Alert Real-Time, ELITechgroup ABI Prism 7300 
10 NucliSENS EasyMag generic 2.0.1 500 55 EBV ELITe MGB Kit, ELITechgroup ABI Prism 7300 
11 NucliSENS EasyMag generic 2.0.1 1000 60 EBV Alert Real-Time, ELITechgroup ABI Prism 7300 
12 NucliSENS EasyMag specific 2.0 500 100 EBV ELITe MGB Kit, ELITechgroup ABI Prism 7300 
13 NucliSENS EasyMag generic 2.0.1 500 55 EBV Alert Real-Time, ELITechgroup ABI Prism 7300 
14 NucliSENS EasyMag generic 2.0.1 500 55 EBV Alert Real-Time, ELITechgroup ABI Prism 7300 
15 Manual extraction QIAamp blood mini kit 200 100 EBV R-gene Argene-Biomerieux ABI Prism 7500 
        
BKV 1 QIA Symphony DSP virus/pathogen (modified) 400 90 BKV Trender Affigene Stratagene xp3000 
2 NucliSENS EasyMag generic 2.0.1 250 25 BKV Alert Real-Time, ELITechgroup ABI Prism 7300 
3 QIA Symphony DSP virus/pathogen (modified) 1000 110 BKV ELITe MGB KIT,  ELITechGroup ABI Prism 7300 
4 NucliSENS EasyMag generic 2.0.1 500 55 in house PCR (target large T region)[16] ABI Prism 7300 
5 NucliSENS EasyMag generic 2.0.1 1000 100 BKV ELITe MGB KIT,  ELITechGroup ABI Prism 7300 
6 x-tractor gene UV light Helix DNA Corbet 400 60 BKV ELITe MGB KIT,  ELITechGroup ABI Prism 7300 
7 NucliSENS EasyMag generic 2.0.1 500 50 BKV ELITe MGB KIT,  ELITechGroup ABI Prism 7500 
8 NucliSENS EasyMag generic 2.0.1 400 60 Light mix Polyomaviruses JC and BK (TibMolBiol) Lightcycler 2.0 
9 NucliSENS EasyMag generic 2.0.1 1000 25 BKV Q-PCR Alert Kit, ELITechGroup ABI Prism 7300 
10 NucliSENS EasyMag generic 2.0.1 500 55 BKV ELITe MGB KIT,  ELITechGroup ABI Prism 7300 
11 NucliSENS EasyMag generic 2.0.1 1000 60 BKV Alert Real-Time, ELITechgroup ABI Prism 7300 
12 NucliSENS EasyMag specific 2.0 500 100 BKV ELITe MGB KIT,  ELITechGroup ABI Prism 7300 
13 NucliSENS EasyMag generic 2.0.1 500 55 BKV ELITe MGB KIT,  ELITechGroup ABI Prism 7300 
14 NucliSENS EasyMag generic 2.0.1 500 55 BKV ELITe MGB KIT,  ELITechGroup ABI Prism 7300 
15 Manual extraction QIAamp blood mini kit 200 100 JC primers - probe + BKV R-gene,  Argene-Biomerieux ABI Prism 7500 
WB, whole blood 
 15 
Table 2. Summary of quantitative performance for CMV plasma, CMV WB, EBV and BKV panels. 
 
 QCMV 2012 panel Sample 
No. of 
values 
Mean ± SD 
(Log copies/ml) 
Inter-lab. CV 
(%) 
Median 
(Log copies/ml) 
Range 
(Log copies/ml) 
CMV plasma  CMV12-01  15 4.43±0.17 3.93 4.43 4.12-4.65 
 CMV12-02 15 3.82±0.29 7.56 3.89 3.29-4.36 
 CMV12-03 14 2.19±0.33 12.65 2.17 1.56-2.53 
 CMV12-04 11 2.05±0.46 19.56 2.00 1.28-2.35 
 CMV12-05 15 3.24±0.48 14.84 3.40 2.04-3.66 
 CMV12-06 15 3.43±0.21 6.19 3.47 2.98-3.80 
 CMV12-07 15 3.46±0.18 5.15 3.50 3.16-3.70 
 CMV12-09 15 3.80±0.21 5.60 3.83 3.29-4.14 
 CMV12-10 15 2.74±0.26 9.30 2.72 2.18-3.14 
CMV WB CMV12-01 13 3.82±0.59 15.33 3.78 2.78-4.56 
 CMV12-02 13 4.83±0.57 11.90 4.96 3.89-5.50 
 CMV12-03 13 3.01±0.43 13.95 3.09 2.32-3.65 
 CMV12-04 13 3.85±0.54 14.06 3.82 3.15-4.51 
 CMV12-05 13 3.03±0.41 13.03 3.08 2.38-3.54 
 CMV12-07 13 4.55±0.50 10.91 4.44 3.84-5.17 
 CMV12-08 9 2.63±0.44 16.57 2.73 1.81-3.05 
EBV EBV12-01 15 2.52±0.30 11.92 2.56 1.97-3.16 
 EBV12-02 15 3.57±0.24 6.89 3.59 3.22-4.20 
 EBV12-03 15 4.93±0.25 5.12 4.87 4.59-5.53 
 EBV12-04 15 4.55±0.23 5.17 4.53 4.26-5.12 
 EBV12-05 15 4.12±0.23 5.61 4.11 3.80-4.68 
 EBV12-06 15 4.26±0.21 5.10 4.20 3.98-4.77 
 EBV12-07 15 4.58±0.23 5.19 4.49 4.32-5.21 
 EBV12-08 15 3.26±0.23 7.02 3.23 2.81-3.81 
 EBV12-09 15 3.09±0.26 8.33 3.10 2.52-3.72 
BKV BK12-02 15 3.58±0.38 10.59 3.64 2.92-4.19 
 BK12-03 15 2.43±0.34 14.54 2.43 1.81-2.90 
 BK12-07 15 1.72±0.48 26.25 1.76 0.90-2.35 
 BK12-08 15 4.64±0.39 8.51 4.66 3.81-5.26 
 BK12-12 15 5.14±0.34 6.58 5.15 4.35-5.56 
